SANTA CLARA, Calif., March 10, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiovascular diagnostic solutions developer, announced today that the results of a my3KG performance study will be made at the Society for Academic Emergency Medicine (SAEM) Annual Meeting, to be held in Boston, MA, June 1-5, 2011.
The study, entitled “A New Computer Algorithm Performs Better than Cardiologists in the Diagnosis of Acute Myocardial Infarction,” will be presented at the SAEM meeting by Dr. Stephen W. Smith, Associate Professor of Emergency Medicine, University of Minnesota and Hennepin County Medical Center (HCMC), Minneapolis MN. Co-investigators in this study included Drs. Victor Romo and James Miner, Emergency Medicine, HCMC; and Drs. Dajuanna Lakireddy, Subba Vanga, and Sudha Bommana, Kansas University Cardiovascular Research Institute, Kansas City, KS.
The SAEM presentation will address a key diagnostic problem in Emergency Department (ED) patients the low diagnostic sensitivity of the standard 12-lead ECG in early diagnosis of acute myocardial infarction (MI).
Dr. Smith commented, “The standard 12-lead ECG plays a critical role in MI diagnosis, but its low sensitivity even with expert physician interpretation - leads to diagnostic delays and errors. To the extent that my3KG can improve diagnostic sensitivity for acute MI, it is an important result that may lead to faster and more accurate MI diagnosis in the ED.”
Dr. Ihor Gussak, NewCardio’s Chief Medical Officer, commented, “We were delighted that Dr. Smith collaborated with us in this study. He is an internationally known and well-respected emergency medicine specialist with particular expertise in clinical electrocardiology and diagnosis of acute coronary syndromes. He is highly influential among ED physicians, who represent a key potential constituency for my3KG. We look forward to the SAEM presentation, and to completing additional studies with Dr. Smith and his colleagues, as we further develop my3KG.”
NewCardio’s innovative 3-D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12L ECG. NewCardio is developing the my3KG solution for urgent diagnosis of serious cardiac conditions, including AMI. In clinical studies to date, the my3KG has shown substantially improved diagnostic accuracy relative to the standard 12L ECG, particularly in the most diagnostically challenging patients (such as those with diabetes and electrical conduction abnormalities). Accordingly, the Company believes that its innovative my3KG solution will substantially improve diagnostic timing and accuracy in life-threatening cardiac conditions, and will thereby improve clinical outcomes for a broad range of cardiac patients. The Company plans to file a 510(k) application in late 2011 or early 2012 for FDA approval to market my3KG in the U.S.
About the Society for Academic Emergency Medicine (SAEM)
The SAEM is dedicated to the improvement of care of the acutely ill and injured patient by improving research and education. To achieve this mission, SAEM influences health policy through forums, publications, inter-organizational collaboration, policy development, and consultation services for physicians, teachers, researchers, and students. SAEM represents excellence and leadership in academic emergency medicine and its values include idealism and quality in all endeavors, nurturing and camaraderie and diversity among members, as well as creative and symbiotic interactions with other organizations.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead ECG. NewCardio’s 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio’s software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Investor Contact: | |
Hayden IR | |
Jeff Stanlis, Partner | |
(602) 476-1821 | |
jeff@haydenir.com | |
SOURCE NewCardio, Inc.
